Obviousness

Obviousness Analysis of US Patent 10166190 under 35 U.S.C. § 103

This analysis identifies combinations of prior art references that would render the claims of US patent 10166190 obvious to a person having ordinary skill in the art (POSA). The primary prior art references establishing the basic tacrolimus compositions are WO2005/020993 and WO2005/020994, which the patent itself acknowledges as disclosing "tacrolimus-containing pharmaceutical compositions... in particular tacrolimus compositions comprising a solid dispersion of tacrolimus in polyethylene glycol (PEG)" [Description].

The common problem addressed by the patent is the known instability of tacrolimus, particularly in solid dispersions, leading to the formation of degradation products, and the need to maintain low concentrations of these impurities throughout the product's shelf-life to meet regulatory standards [Description]. A POSA in the field of pharmaceutical formulation would possess knowledge of drug stability, excipient selection, and common methods for preventing chemical degradation, including pH control and metal chelation.

Obviousness of Independent Claim 1 (and related compositional claims 16, 19, 28, 29)

Independent Claim 1: A pharmaceutical composition comprising a solid dispersion of tacrolimus in a mixture of a vehicle and a stabilizing agent capable of providing a pH below 7 in the composition.

Combination of Prior Art:

1. WO2005/020993 (or WO2005/020994): These references teach a pharmaceutical composition comprising a solid dispersion of tacrolimus in a vehicle, specifically polyethylene glycol (PEG) [Description]. This establishes the core composition of tacrolimus dispersed in a vehicle.
2. General Pharmaceutical Knowledge: It is a well-established principle in pharmaceutical formulation that active pharmaceutical ingredients (APIs) can degrade, and that various excipients, including pH-adjusting agents and chelating agents, are used to enhance stability. The patent itself highlights the "need for preventing the formation of degradation products from tacrolimus" and that "stabilizing compounds preventing degradation of the active substance... are desired" [Description]. The patent also notes that the major degradation product, 8-epitacrolimus, "may be formed... under mild basic conditions" [Description]. Furthermore, "traces of e.g. metal ions will inevitably occur in the vehicle due to the use of equipment and excipients containing metal ions" [Description, Example 3], motivating the use of chelating agents.

Motivation to Combine:
A POSA would be motivated to combine the known tacrolimus solid dispersion (from WO2005/020993) with a stabilizing agent to address the recognized problem of tacrolimus degradation. Knowing that 8-epitacrolimus forms under "mild basic conditions" [Description], a POSA would naturally be motivated to introduce a pH-regulating agent to maintain a pH below 7 to counteract this degradation. Given the inevitable presence of metal ions in formulations, and the fact that such ions can catalyze degradation, a POSA would also be motivated to include a chelating agent to mitigate this effect. Tartaric acid, specifically mentioned in the patent as a preferred stabilizing agent and a chelating agent [Description], is a common pharmaceutical excipient with both acidic and chelating properties. Its selection and incorporation into the tacrolimus solid dispersion to achieve a stable composition would therefore be obvious. The subsequent optimization of the concentration of tartaric acid (as claimed in claims 28 and 29) to achieve a desired stability profile would be considered routine experimentation for a POSA.

Obviousness of Independent Claim 15 (method claim)

Independent Claim 15: A method for reducing the concentration of tacrolimus degradation products in a pharmaceutical composition comprising tacrolimus as the active ingredient, wherein a stabilizing agent is incorporated into the composition.

Combination of Prior Art:

1. Tacrolimus as an active ingredient with known instability: The patent's background section clearly establishes that tacrolimus is an active ingredient and that "the presence of degradation products in a pharmaceutical formulation... is highly undesirable" [Description]. This highlights the long-standing problem of tacrolimus degradation.
2. General Pharmaceutical Practice: It is a fundamental and well-known practice in pharmaceutical development to incorporate stabilizing agents into drug compositions to reduce or prevent the formation of degradation products. The patent itself states that "stabilizing compounds preventing degradation of the active substance... are desired" [Description].

Motivation to Combine:
A POSA, confronted with the acknowledged instability of tacrolimus and the need to reduce degradation products, would be readily motivated to employ the well-established pharmaceutical strategy of incorporating a stabilizing agent into the composition. This is a direct and conventional approach to address drug instability and is a standard part of formulation development.

Obviousness of Independent Claims 21, 22, 23, 24, 25, 26, and 27 (stability criteria claims)

Independent Claims 21-27: These claims define pharmaceutical compositions comprising tacrolimus that meet specific stability criteria regarding the levels of 8-epitacrolimus and other degradation products after storage under various conditions.

Combination of Prior Art:

1. Underlying Tacrolimus Composition and Stabilizing Agent: The foundation of these claims rests on a tacrolimus solid dispersion containing a stabilizing agent, as rendered obvious by the arguments for Claim 1.
2. Regulatory Requirements and Industry Standards: The International Conference of Harmonization (ICH) guidelines (e.g., ICH Topic 3 Q B (R2)) set limits for degradation products in pharmaceutical formulations [Description]. The patent notes that the ICH limit is typically 0.5% for a single degradation product for certain daily dosages [Description]. Pharmaceutical manufacturers are routinely required to demonstrate that their products meet these stability specifications under various storage conditions (e.g., 25°C/60% RH, 40°C/75% RH) for specified durations.

Motivation to Combine:
Once a POSA is motivated to stabilize tacrolimus formulations using a stabilizing agent, the subsequent motivation is to ensure the product meets acceptable stability profiles for regulatory approval and commercial viability. Achieving specific thresholds for degradation products (e.g., less than 0.5% or less than 0.2% of 8-epitacrolimus, or specific increases in these levels) after various standard storage conditions and durations is a routine objective in pharmaceutical development. The selection and optimization of known stabilizing agents (such as tartaric acid, which the patent's examples demonstrate can achieve these stability profiles [Description, Example 3]) to meet these predefined stability specifications would be a matter of routine experimentation for a POSA striving to develop a marketable and compliant pharmaceutical product. The patent itself recognizes that "prevention of degradation does not always follow a simple linear effect, but windows of optimal effect may exist" [Description], implying that optimization is expected. While the specific identification of other degradation products (Diene, C4-epimer diene, Regioisomer A) might be novel, the motivation to control all relevant degradation products to within acceptable limits using known stabilization techniques remains obvious.